MRK240628C114000
- 0.00
- 0.000.00%
Merck & Co Newsroom
Merck & Co Unusual Options Activity
Financial giants have made a conspicuous bearish move on Merck & Co. Our analysis of options history for Merck & Co (NYSE:MRK) revealed 8 unusual trades.Delving into the details, we found 12% of trade
Roche's TIGIT therapy failed to achieve its main goal. Biotechnology stocks like Compugen (CGEN.US) suffered heavy losses before the market opened.
A class of new anti-cancer drugs (referred to as new 'anti-TIGIT therapy') developed by some biotech companies listed on the US stock market have seen a significant drop in stock prices before the market due to the failure of a Roche, a Swiss pharmaceutical giant, to develop a similar drug in Phase 2/3 clinical trials.
Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients
On Thursday, Roche Holdings AG (OTC:RHHBY) said that the Phase 2/3 SKYSCRAPER-06 study of tiragolumab plus Tecentriq (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as first-line
HKEX anomaly | Kexing Bioproducts-B (06990) currently up more than 7%, the company partners with Merck to go overseas. Institutions said that the commercialization of core products is imminent.
Shares of Kelun-Bio (06990) rose over 7%, as of press time, up 7.44% at HKD 163.2, with a turnover of HKD 55.3385 million.
Top High Quality Stocks That Pay Dividends - UBS
Merck (NYSE:MRK) Seems To Use Debt Quite Sensibly
MRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame during the COVID-19 pandemic.
Insights Into Merck & Co's Performance Versus Peers In Pharmaceuticals Sector
In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry com
Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner
Merck and partner Orion Corporation announced that they have agreed to mutually exercise the option that will provide Merck global exclusive rights to develop and commercialize opevesostat (previously MK-5684)
The Investment Guide for the 2024 USA Election is here! The best deployment time has come. Which US stocks are worth paying attention to?
Bank of America stated that the average monthly ROI of the S&P 500 index in the fourth year of a presidential cycle shows mediocre performance from January to May, a summer rebound from June to August, a fall before the election in September to October, and a post-election rebound in November and December.
5 Biggest Winners, 5 Biggest Losers From Dow Jones Industrial Average In First Half 2024
Broad stock market indexes like the S&P 500 hit all-time highs in the first half of 2024.The Dow Jones Industrial Average also hit all-time highs, but saw a smaller return in the first half of the yea
Health Care Up on Defensive Demands -- Health Care Roundup
Health-care companies rose as weak economic data spurred demand for defensive stocks.
Market Whales and Their Recent Bets on MRK Options
Investors with a lot of money to spend have taken a bearish stance on Merck & Co (NYSE:MRK).And retail traders should know.We noticed this today when the positions showed up on publicly available opti
Express News | Merck Shares up 3.8%
Orion Upgrades FY24 Outlook After Modifying Agreement With Merck & Co
Orion (ORNAV.HE, ORNBV.HE) upwardly revised its full-year outlook after its development and commercialization deal with US-based Merck & Co was converted into a global license for the latter, accordin
Express News | Merck and Orion announced that Opevesostat will be exclusively licensed by Merck.
Merck, Orion Convert Collaboration Into Exclusive License
By Colin Kellaher Merck & Co. and Finland's Orion have agreed to convert a 2022 co-development and co-commercialization agreement into an exclusive global license for Merck. The companies on Monday
Express News | N-Power Medicine: Collaborates With Merck to Expand Oncologist and Patient Access to Clinical Trials
Merck And Orion Announce Mutual Exercise Of Option To Convert Opevesostat Co-Commercialization Agreement Into An Exclusive Global License For Merck; Orion Now Eligible For Development Milestones Up To $30M, Regulatory Milestones Up To $625M, And Sales...
Merck And Orion Announce Mutual Exercise Of Option To Convert Opevesostat Co-Commercialization Agreement Into An Exclusive Global License For Merck; Orion Now Eligible For Development Milestones Up To
Express News | Merck & Co Inc - Orion Eligible for up to $1.63 Billion in Milestone Payments